Home > Insider Trading > Filing (0000899243-15-010287)

Filing Details

Accession Number:: 0000899243-15-010287
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-12-22 16:19:29
Reporting Period:: 2015-12-18

Filing Date:: 2015-12-22
Accepted Time:: 2015-12-22 16:19:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1285819	Omeros Corp	OMER	Pharmaceutical Preparations (2834)	911663741

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1472163	S. Marcia Kelbon	201 Elliott Avenue West Seattle WA 98119	Vp Patent And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-12-18	15,154	$0.98	146,280	No	4	M	Direct
Common Stock	Disposition	2015-12-18	15,154	$15.00	131,126	No	4	S	Direct
Common Stock	Acquisiton	2015-12-19	7,300	$4.10	138,426	No	4	M	Direct
Common Stock	Acquisiton	2015-12-22	746	$0.98	139,172	No	4	M	Direct
Common Stock	Disposition	2015-12-22	746	$15.00	138,426	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-12-18	15,154	$0.00	15,154	$0.98
Common Stock	Stock Option (Right to Buy)	Disposition	2015-12-19	7,300	$0.00	7,300	$4.10
Common Stock	Stock Option (Right to Buy)	Disposition	2015-12-22	746	$0.00	746	$0.98

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
143,946	2016-12-11	No	4	M	Direct
112,700	2022-01-07	No	4	M	Direct
143,200	2016-12-11	No	4	M	Direct

Footnotes

Open market sale pursuant to a 10b5-1 trading plan adopted by the reporting person on June 3, 2014, at which time the trading schedule, including sale periods, price and the number of shares to be sold, was established, in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. This Rule 10b5-1 plan provides for fixed sales of a total of 175,000 shares, by exercise of options otherwise expiring on December 11, 2016, over a one-year period beginning in November 2015, with sale periods commencing approximately monthly and with approximately 15,900 shares to be sold in each sale period. Following the establishment of the 10b5-1 trading plan on June 3, 2014, and consistent with its applicable trading rules, Ms. Kelbon has had no further input or control over the specific share sales or timing of those sales under the plan.
(continued from Footnote 1) A portion of the proceeds are being used to fund the exercise and holding of other options and may also be used to fund the costs of and taxes on the future exercise and holding of additional other options. These sales of shares occurred during the second monthly sale period under this trading plan.
The option vested and became exercisable in 48 equal monthly installments. The first installment became exercisable on November 1, 2005 and subsequent installments became exercisable on each monthly anniversary thereafter. On December 18, 2015, options to purchase 15,154 shares were exercised and on December 22, 2015, options to purchase 746 shares were exercised. These shares were sold upon exercise as reflected in Table I.
The option vested and became exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2011. Installments vested and became exercisable on each monthly anniversary thereafter. On December 19, 2015, options to purchase 7,300 of these shares were exercised and held.